Last reviewed · How we verify
NCT05612659: PSD
Developing an EEG Probe for Studying and Modulating Cognitive Control
NA trial testing Transcranial Electrical stimulation in Post-stroke Depression in 30 participants. Completed in 30 May 2024.
31 March 2024
Quick facts
| Lead sponsor | University of Cincinnati |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 28 September 2022 |
| Primary completion | 31 March 2024 |
| Estimated completion | 30 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transcranial Electrical stimulation
- Transcutaneous direct current stimulation
Conditions studied
- Post-stroke Depression — all drugs for Post-stroke Depression →
Sponsor
University of Cincinnati
Who can join
Adults 18 to 80, any sex, with Post-stroke Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate effects of transcranial current stimulation (tES) and transcutaneous direct current stimulation (tsDCS) associated changes on fronto-parietal EEG and cognitive performance in patients with post stroke depression (PSD)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05612659
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-stroke Depression
Currently open trials in the same condition.
- NCT07294274 — Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke · recruiting
- NCT06598670 — Transcranial Direct Current Stimulation on Post Stroke Depression · NA · recruiting
Other University of Cincinnati trials
Trials by the same sponsor.
- NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
- NCT07528638 — Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) · NA · not yet recruiting
- NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
- NCT07447895 — Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies · NA · not yet recruiting
- NCT07231588 — Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05612659 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cincinnati
- Last refreshed: 27 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05612659.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing